Will FDA approve dordaviprone for recurrent H3 K27M-mutant diffuse glioma by Q3 2025? | Binary | | | 8 days ago | |
How will Chimerix utilize the $30 million credit facility by end of 2025? | Categorical | | | 8 days ago | |
Will Chimerix secure full $30 million credit facility from Silicon Valley Bank by end of 2024? | Binary | | | 8 days ago | |
Will Chimerix announce a strategic partnership with a major pharmaceutical company by Q3 2025? | Binary | | | 8 days ago | |
How will Chimerix's stock price move within a week of FDA decision by Q3 2025? | Categorical | | | 8 days ago | |
Will Chimerix secure additional funding beyond $30 million by end of 2025? | Binary | | | 9 days ago | |
What will be the FDA's decision on dordaviprone by Q3 2025? | Categorical | | | 8 days ago | |
Will Dordaviprone be commercially available in the U.S. by end of 2025? | Binary | | | 9 days ago | |
What will be the FDA's decision on Dordaviprone NDA by end of 2025? | Categorical | | | 9 days ago | |
How will Chimerix stock perform relative to biotech index post-FDA decision? | Categorical | | | 9 days ago | |
Will FDA grant accelerated approval for Dordaviprone by end of 2025? | Binary | | | 9 days ago | |
What market share will Dordaviprone capture in first year post-approval? | Categorical | | | 9 days ago | |
